Soler, G, Grávalos, C, Rivera, F, Safont, MJ, Virgili, AC, Valladares-Ayerbes, M, Ferreiro-Monteagudo, R, Ortiz-Morales, MJ, Polo-Marques, E, Kornusova-Bersheva, I, Soustre, E, Yao, WY, Élez, E. Predictive factors of efficacy for FTD/TPI plus bevacizumab in refractory metastatic colorectal cancer patients: a subanalysis of the Spanish cohort from the SUNLIGHT phase III trial. Clinical & Translational Oncology. 2025; 27(11)DOI:10.1007/s12094-025-03907-z. PMID:40338282. IF:2.500(Q3/6D).

Cortellini, A, Garbo, E, La Cava, G, Citarella, F, Santo, V, Brunetti, L, Pinato, DJ, Naidoo, J, Loza, M, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Montrone, M, Owen, DH, Signorelli, D, Li, MJ, Camerini, A, Halmos, B, Vincenzi, B, Metro, G, Yendamuri, S, Grossi, F, Josephides, E, Tomasik, B, Giusti, R, Bria, E, Sebastian, M, Rost, M, Acker, F, Landi, L, Mazzoni, F, Morabito, A, Leonetti, A, Cantini, L, Mountzios, G, Kalvapudi, S, O'Reilly, D, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Piedra, A, Cortinovis, DL, Tonini, G, Minuti, G, Mezquita, L, Gorria, T, Beninato, T, Lo Russo, G, Prelaj, A, De Giglio, A, Biello, F, Nana, FA, Dingemans, AMC, Aerts, JG, Ferrara, R, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, MC, Wakelee, HA, Nassar, A, Ricciuti, B, Soda, P, Caruso, CM, Guarrasi, V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression = 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. LUNG CANCER. 2025; 209DOI:10.1016/j.lungcan.2025.108799. PMID:41108882. IF:4.400(Q1/2D).

Yang, JCH, Wang, MZ, Doucet, L, Fan, Y, Lv, DQ, Sun, ML, Huang, DZ, Greillier, L, Planchard, D, Hong, QY, Mazieres, J, Felip, E, Li, XY, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Pellini, B, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, RM, Zalcman, G, Carpeno, JD, Di Noia, V, Parra, HS, Streich, G, Lee, DH, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquin, AB, Liu, GF, Antonuzzo, L, Hinojal, GF, Le, XN, Zheng, L, Jänne, PA. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(29)DOI:10.1200/JCO-25-00788. PMID:40923280. IF:41.900(Q1/1D).

de la Peña, FA, Martínez-Ramos, D, Juan-Vidal, O, Gómez-Balaguer, M, Miguélez, M, Páez, D, Arrazubi, V, González, CH. Oncological needs in transgender patients. Clinical & Translational Oncology. 2025; 27(10)DOI:10.1007/s12094-025-03917-x. PMID:40251439. IF:2.500(Q3/6D).

Suárez, C, Torras, OR, Barrera, RM, Sánchez, AR, Palacios, GA, Manshino, AMB, Núñez, NF, Vidal, MJM, Carbonero, IG, Calvo, OF, Sarrió, RG, Herrero, GC, Afonso, JA, Fita, MJJ, Padró, JG, Quintela, ML, Rodriguez-Vida, A, Perez, CH, Colmenero, AM, Martin, RC, de España, CG, Palau, CM, Ortega, EM, Gallardo, E. Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Clinical Genitourinary Cancer. 2025; 23(5)DOI:10.1016/j.clgc.2025.102402. PMID:40830022. IF:2.700(Q2/3D).

Palmerini, E, Meazza, C, Tamburini, A, Márquez-Vega, C, Bisogno, G, Fagioli, F, Ferraresi, V, Milano, GM, Coccoli, L, Rubio-San-Simón, A, Gallego, O, Riestra, MEL, Manzitti, C, Mora, J, Vaz-Salgado, MA, Luksch, R, Mata, C, Pierini, M, Carretta, E, Cesari, M, Paioli, A, Marrari, A, Scotlandi, K, Serra, M, Asaftei, SD, Gambarotti, M, Picci, P, Ferrari, S, Valverde, C, Ibrahim, T, Broto, JM. Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(28)DOI:10.1200/JCO-25-00210. PMID:40825172. IF:41.900(Q1/1D).